Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $336.08M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.18M
Average 0.09M
LYEL EBITDA Margin
EBITDA as a percentage of revenue.
Lyell Immunopharma, Inc.NASDAQ: LYEL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -1091050.0%
EBITDA Margin was -1091050.0% in Q1 FY2026, down 394564.3 pp from a year earlier. On a trailing-twelve-month basis it was -770932.3%, down 482924.6 pp year over year. Over 3 fiscal years it narrowed by 730107.8 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -824406.2% for the fiscal year ending Dec 2026, down from -730302.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1091050.0%+1214383.3 pp QoQ
- Last fiscal yearDec 2025
- -730302.8%-401379.8 pp YoY
- LTMMar 2026
- -770932.3%-482924.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -730302.8%
- Year-over-year change
- -401379.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -730302.8% | -401379.8pp |
| FY2024 | 2024-12-31 | -328923.0% | -164013.7pp |
| FY2023 | 2023-12-31 | -164909.2% | -164714.3pp |
| FY2022 | 2022-12-31 | -195.0% | +2026.6pp |
| FY2021 | 2021-12-31 | -2221.5% | — |
EBITDA Margin vs competitors
How LYEL compares with its peers on the latest reported figures
- LYEL's LTM Mar 2026 EBITDA Margin of -770932.3% is the lowest of the 6 companies compared; the peer median is -1740.8%.
- Its year-over-year change of -482924.6 pp is the lowest of 4, against a peer median of +29.0 pp.
- Over three fiscal years its change of -730107.8 pp compares with a peer median of -167.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -2.4% | +29.0 pp | +11.8 pp | |
| LTM Mar 2026 | -258.7% | +387.8 pp | +719.4 pp | |
| LTM Mar 2026 | -1740.8% | -1565.2 pp | -167.5 pp | |
| LTM Mar 2026 | -8478.5% | — | -15524.4 pp | |
GNLXGenelux Corporation | LTM Mar 2026 | -400537.5% | — | -394621.9 pp |
| LTM Mar 2026 | -770932.3% | -482924.6 pp | -730107.8 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding LYEL) | -1740.8% | +29.0 pp | -167.5 pp | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.65M | 84.68M | 130K | 61K | 36K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.54M |
| Gross Profit | 10.65M | 84.68M | 130K | 61K | (11.5M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| Research & Development | 138.69M | 159.19M | 182.95M | 171.6M | 158.68M |
| Selling, General & Admin | 89.06M | 117.31M | 66.98M | 52.04M | 45.14M |
| Operating Expenses | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M |
| Depreciation & Amortization | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M |
| EBITDA | (236.6M) | (165.1M) | (214.38M) | (200.64M) | (262.91M) |
| EBITDA Margin | -2221.5% | -195.0% | -164909.2% | -328923.0% | -730302.8% |
| Operating Income | (214.78M) | (187.06M) | (247.01M) | (358.76M) | (203.77M) |
| Operating Margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| Interest Income | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (35.44M) | 3.94M | 12.38M | 15.76M | (70.67M) |
| Income Before Tax | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Pre-Tax Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Net Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (Basic) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| EPS (Diluted) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| Weighted Avg Shares | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
| Weighted Avg Shares (Diluted) | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.